Qube Research & Technologies (QRT)
RYTM icon

Qube Research & Technologies (QRT)’s Rhythm Pharmaceuticals RYTM Stock Holding History

Qube Research & Technologies (QRT)’s Portfolio RYTM Stock Details RYTM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$24.2M Sell
277,943
-32,976
-11% -$3.21M 0.03% 778
2025
Q4 		$33.3M Buy
310,919
+72,100
+30% +$7.65M 0.03% 669
2025
Q3 		$24.1M Sell
238,819
-1,526
-0.6% -$142K 0.02% 812
2025
Q2 		$15.2M Buy
240,345
+24,152
+11% +$1.48M 0.02% 1037
2025
Q1 		$11.5M Buy
216,193
+120,958
+127% +$6.71M 0.01% 1042
2024
Q4 		$5.33M Buy
+95,235
New +$5.26M 0.01% 1458
2023
Q2 		– Sell
-291,314
Closed -$5.2M – 2926
2023
Q1 		$5.2M Buy
291,314
+110,757
+61% +$2.78M 0.02% 656
2022
Q4 		$5.26M Buy
+180,557
New +$4.64M 0.03% 651
2022
Q3 		– Sell
-28,794
Closed -$119K – 2952
2022
Q2 		$119K Buy
+28,794
New +$158K ﹤0.01% 1876
2021
Q4 		– Sell
-15,453
Closed -$202K – 2906
2021
Q3 		$202K Sell
15,453
-7,771
-33% -$119K ﹤0.01% 1659
2021
Q2 		$455K Sell
23,224
-3,452
-13% -$71.7K 0.01% 1333
2021
Q1 		$567K Buy
+26,676
New +$774K 0.01% 1103
2020
Q4 		– Sell
-15,183
Closed -$329K – 2147
2020
Q3 		$329K Buy
+15,183
New +$348K ﹤0.01% 1199

Other funds holding RYTM

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return

Qube Research & Technologies (QRT)'s RYTM Position: Q1 2026 in Review

Qube Research & Technologies (QRT) reduced its Rhythm Pharmaceuticals (RYTM) stake by 11% in Q1 2026, selling an estimated $3.21M and leaving 277,943 shares worth $24.2M. The position accounts for 0.03% of the portfolio, ranked #778.

Qube Research & Technologies (QRT) first reported a position in RYTM in Q3 2020 and has held it in 13 quarters since. The position peaked at $33.3M in Q4 2025. 285 funds tracked by Wall St. Rank hold RYTM as of Q1 2026.

  • Qube Research & Technologies (QRT) held 277,943 shares of Rhythm Pharmaceuticals worth $24.2M as of Q1 2026.
  • Qube Research & Technologies (QRT) sold 32,976 Rhythm Pharmaceuticals shares in Q1 2026, an estimated $3.21M.
  • Rhythm Pharmaceuticals made up 0.03% of Qube Research & Technologies (QRT)'s portfolio in Q1 2026, its #778 holding.
  • Qube Research & Technologies (QRT) first reported a position in Rhythm Pharmaceuticals in Q3 2020 and has held it in 13 quarters since.
  • Qube Research & Technologies (QRT)'s Rhythm Pharmaceuticals position peaked at $33.3M in Q4 2025.
  • 285 funds tracked by Wall St. Rank held Rhythm Pharmaceuticals as of Q1 2026.

Based on Qube Research & Technologies (QRT)'s 13F filing for Q1 2026, filed 15 May 2026.